Adjuvant therapy for high-risk liver cancer after liver transplant
Part of Cancer, Digestive system clinical trials.
This trial tests if additional treatment after a liver transplant can help prevent liver cancer from coming back. It is for people who had high-risk features of their cancer before or after the transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a liver transplant 4 to 8 weeks ago for liver cancer.
- Your liver cancer was high-risk, like it was larger than Milan criteria, had blood vessel invasion, or had satellite nodules.
- You have good liver function and can care for yourself (ECOG 0-1).
- You have not had other cancer treatments before transplant except TACE, herbal medicine, or interferon.
- You do not have active bleeding, blood clots, or uncontrolled infections.
- You agree to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of two therapies—targeted chemotherapy delivered directly to the liver (TACE) plus immunotherapy (atezolizumab) and a targeted drug (bevacizumab)—can keep liver cancer from coming back after surgery. It is for people whose tumors can be surgically removed but are at high risk of recurrence.
This trial tests whether a combination of two drugs (tislelizumab and lenvatinib) given before surgery can lower the risk of liver cancer coming back in people with early-stage but high-risk disease.
This trial studies whether adding atezolizumab and bevacizumab after complete liver cancer surgery can lower the chance the cancer comes back. It also uses “multi-omics” tests (special lab tests on your tissue/blood) to help predict who is more likely to respond or resist treatment.
This trial tests a combination of two drugs (atezolizumab and bevacizumab) plus a targeted radiation treatment (Y-90 radioembolization) for people with liver cancer who are waiting for a liver transplant. The goal is to see if this treatment can help control the cancer and improve transplant outcomes.
This trial tests whether adding two drugs (atezolizumab and bevacizumab) before and after surgery can lower the chance of liver cancer coming back in people with high-risk HCC. You must be eligible for surgical removal of your tumor.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (bevacizumab) after surgery or ablation for liver cancer that has a high chance of coming back. The goal is to see if this treatment can reduce the risk of recurrence.
Hear when a new Liver Transplant; Complications trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.